Allyx Therapeutics Awarded $3.3 Million NIH Grant to Support Further Clinical Studies of Lead Candidate ALX-001
15 oct. 2024 07h05 HE
|
Allyx Therapeutics Inc.
Allyx Therapeutics has been awarded a $3.3 million grant as part of the NIH's Small Business Innovation Research Commercial Readiness Pilot program
Allyx Therapeutics Announces First Parkinson’s Disease Patient Treated with ALX-001
04 sept. 2024 08h00 HE
|
Allyx Therapeutics Inc.
Allyx Therapeutics first patient first patient has been dosed with its lead compound, ALX-001, in new Parkinson's Disease clinical study
Allyx Therapeutics Announces First Alzheimer’s Disease Patient Treated with Lead Compound ALX-001
11 juin 2024 08h00 HE
|
Allyx Therapeutics Inc.
Allyx Therapeutics Announces First Alzheimer’s Disease Patient Treated with Lead Compound ALX-001.
Allyx Therapeutics Announces Positive Phase 1b Multiple Ascending Dose Data and Advances ALX-001 to Patients
11 mars 2024 08h05 HE
|
Allyx Therapeutics Inc.
Allyx Therapeutics Announces Positive Phase 1b Multiple Ascending Dose Data and Advances ALX-001 to Patients
Allyx Therapeutics Announces Expansion into Parkinson’s Disease Clinical Research with Lead Compound ALX-001 Following IND Acceptance
05 mars 2024 08h00 HE
|
Allyx Therapeutics Inc.
Allyx Therapeutics Announces Expansion into Parkinson’s Disease Clinical Research with Lead Compound ALX-001 Following IND Acceptance
Allyx Therapeutics Lead Compound ALX-001 is Safe and Tolerable at Doses, Achieving Full Brain Target Engagement in Healthy Older Adults
30 oct. 2023 08h30 HE
|
Allyx Therapeutics Inc.
Allyx Therapeutics Phase 1a Clinical Data Presented at Clinical Trials on Alzheimer's Disease Meeting Support Continued Clinical Development
Allyx Therapeutics to Present Phase 1 Data for Lead Compound ALX-001 at the 16th Clinical Trials on Alzheimer's Disease Meeting
19 oct. 2023 16h05 HE
|
Allyx Therapeutics Inc.
Allyx Therapeutics presents Phase 1 ALX-001 data at CTAD. ALX-001 is a small molecule with unique mechanism at mGluR5 to protect and preserve synapses.